Media coverage about CoLucid Pharmaceuticals (NASDAQ:CLCD) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.6762068972762 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

ILLEGAL ACTIVITY WARNING: “CoLucid Pharmaceuticals (CLCD) Given Daily News Sentiment Rating of 0.10” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/16/colucid-pharmaceuticals-clcd-given-daily-news-sentiment-rating-of-0-10.html.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Insider Buying and Selling by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.